← FDA DRUG APPROVALS

FDA NDA · NDA017027

LIPO-HEPIN

Sponsor: 3M

APPLICATION
NDA017027
TYPE
NDA
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

LIPO-HEPINDiscontinued
HEPARIN SODIUM 10,000 UNITS/ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 20,000 UNITS/ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 40,000 UNITS/ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 15,000 UNITS/0.5ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 10,000 UNITS/0.5ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 1,000 UNITS/0.5ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 5,000 UNITS/ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 1,000 UNITS/ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 20,000 UNITS/0.5ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 7,500 UNITS/0.5ML · INJECTABLE · INJECTION
LIPO-HEPINDiscontinued
HEPARIN SODIUM 5,000 UNITS/0.5ML · INJECTABLE · INJECTION
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →